ZIOPHARM Oncology (ZIOP) Downgraded by BidaskClub

BidaskClub lowered shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a sell rating to a strong sell rating in a research report sent to investors on Thursday morning.

Several other research analysts also recently weighed in on ZIOP. ValuEngine downgraded shares of ZIOPHARM Oncology from a hold rating to a sell rating in a research report on Friday, September 15th. HC Wainwright restated a buy rating and set a $9.50 price target on shares of ZIOPHARM Oncology in a research report on Tuesday, November 7th. Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a hold rating to a buy rating and set a $5.25 price target for the company in a research report on Friday, November 10th. Finally, Raymond James Financial restated a hold rating on shares of ZIOPHARM Oncology in a research report on Monday, December 11th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of $12.67.

ZIOPHARM Oncology (NASDAQ:ZIOP) traded up $0.10 on Thursday, hitting $4.36. 1,311,400 shares of the company traded hands, compared to its average volume of 1,862,778. ZIOPHARM Oncology has a 52-week low of $3.77 and a 52-week high of $7.88. The firm has a market cap of $618.96, a P/E ratio of -8.38 and a beta of 1.44.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The company had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.66 million. During the same quarter last year, the company earned ($0.11) EPS. The firm’s revenue for the quarter was up .0% on a year-over-year basis. analysts predict that ZIOPHARM Oncology will post -0.54 earnings per share for the current year.

In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper acquired 6,440 shares of the business’s stock in a transaction on Wednesday, November 8th. The stock was bought at an average price of $4.68 per share, for a total transaction of $30,139.20. Following the acquisition, the chief executive officer now owns 1,083,731 shares in the company, valued at $5,071,861.08. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 10.40% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Chevy Chase Trust Holdings Inc. purchased a new stake in shares of ZIOPHARM Oncology in the 3rd quarter valued at approximately $104,000. Amalgamated Bank grew its stake in shares of ZIOPHARM Oncology by 12.9% in the 2nd quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 1,924 shares during the period. Oppenheimer & Co. Inc. grew its stake in shares of ZIOPHARM Oncology by 50.0% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 6,000 shares during the period. Adell Harriman & Carpenter Inc. purchased a new stake in shares of ZIOPHARM Oncology in the 3rd quarter valued at approximately $141,000. Finally, Steward Partners Investment Advisory LLC purchased a new stake in shares of ZIOPHARM Oncology in the 3rd quarter valued at approximately $145,000. Institutional investors own 40.23% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “ZIOPHARM Oncology (ZIOP) Downgraded by BidaskClub” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://stocknewstimes.com/2018/01/15/ziopharm-oncology-ziop-downgraded-by-bidaskclub.html.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply